Continuous intravenous administration of vancomycin in medical intensive care unit patients

Journal of Critical Care

Volumn 28, Issue 1, 2013, Pages 9-13

  Saugel, Bernd ^a   Nowack, Marisa C M ^a   Hapfelmeier, Alexander ^a   Umgelter, Andreas ^a   Schultheiss, Caroline ^a   Thies, Philipp ^a   Phillip, Veit ^a   Eyer, Florian ^a   Schmid, Roland M ^a   Huber, Wolfgang ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Continuous infusion; Critical care; Intensive care unit; Intermittent infusion; Therapeutic drug monitoring; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; ETHNIC GROUP; FEMALE; GERMAN; GRAM POSITIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; RETROSPECTIVE STUDY; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; VANCOMYCIN;

EID: 84870788958     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.02.003     Document Type: Article

References (19)

1. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
2. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
3. Chua K., Howden B.P. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. Curr Opin Infect Dis 2009, 22:525-534.
4. Moellering R.C. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006, 42(Suppl 1):S3-S4.
5. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
6. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006, 42(Suppl 1):S35-S39.
7. Rybak M.J., Lomaestro B.M., Rotschafer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
8. Roberts J.A., Lipman J., Blot S., et al. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Curr Opin Crit Care 2008, 14:390-396.
9. Pea F., Furlanut M., Negri C., et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009, 53:1863-1867.
10. Annane D., Bellissant E., Cavaillon J.M. Septic shock. Lancet 2005, 365:63-78.
11. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011, 66(Suppl 2):ii25-ii31.
12. Llopis-Salvia P., Jimenez-Torres N.V. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006, 31:447-454.
13. Wilhelm M.P., Estes L. Symposium on antimicrobial agents-Part XII. Vancomycin. Mayo Clin Proc 1999, 74:928-935.
14. Howden B.P., Ward P.B., Charles P.G., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
15. Sakoulas G., Gold H.S., Cohen R.A., et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006, 57:699-704.
16. Wysocki M., Delatour F., Faurisson F., et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467.
17. Jeurissen A., Sluyts I., Rutsaert R. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 2011, 37:75-77.
18. Hutschala D., Kinstner C., Skhirdladze K., et al. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 2009, 111:356-365.
19. Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005, 33:1983-1987.